Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Docetaxel in Recurrent Uterine Carcinosarcoma
NCT00114218Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- Mar 2005
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and docetaxel in uterine carcinosarcoma (UCS), sponsored by GOG Foundation. Primary endpoints: Objective Tumor Response Rate at 5 years and Incidence of Adverse Effects Grade 3 or Greater at 5 years. Started Mar 2005; status: completed.
02
Drugs
gemcitabinedocetaxel
03
Conditions
uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT00114218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114218.